CIN: L15142RJ1991PLC006353



Date: 14th August, 2023

To, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 (Maharashtra)

(BY BSE LISTING CENTRE)

Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter ended on 30th June, 2023 and Limited Review Report on Un-audited Financial Results for the quarter ended on 30th June, 2023.

You are requested to kindly take the same on record.

Thanking You, Yours Faithfully

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD Company Secretary

AMIT KUMAR MODI COMPANY SECRETARY & COMPLIANCE OFFICER M. NO.: A29371

Encl: a/a

SARDA PROTEINS LTD CIN: L15142RJ1991PLC006353

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)

Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

	Particulars	Three Months Ended on 30.06.2023 Un-Audited	Preceding Three Months Ended on 31.03.2023 Audited	Corresponding Three Month 30.06.2022 Un-Audited	Year Ended 31.03.2023 Audited
1.	Revenue from operations	23:58	73.81	-	579.52
П	Other Income	4.09	4.05	5.17	15.98
Ш.	Total Revenue (I+II)	27.67	77.86	5.17	595.50
IV.	Expenses:				
	Cost of Material Consumed		-	1 (•).	-
	Purchase of Stock -in- Trade	23.63	71.36		571.77
-	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-			5
-	Employee Benefit Expenses	2.74	3.11	3.44	13.48
-	Finance Cost	-			-
	Depreciation and Amoritation Expenses	-	-	1.51	
	Other expenses	1.55	2.76	500	8.96
	Total Expenses (IV)	27.92	77.23	4.95	594.21
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(0.25)	0.63	0.22	1.29
VI.	Exceptional Items			-1	-
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	(0.25)	0.63	0.22	1.29
VIII.		-		(-	
IX	Profit/(Loss) before Tax (V-VI)	(0.25)	0.63	0.22	1,29
X.	Tax Expense:				
	(1) Current Tax	-	2801		-
	(2) Deferred Tax		4,60		4.60
XI.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(0.25)	(3.97)	0.22	(3.31
XIL		-	-	1	
XIII.		-	- 2	3 -	
XIV					-
XV.		(0.25)	(3.97)	0.22	(3.31
XVI					
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss			1	-
	B (i) Items will be reclassified to Profit or Loss		Same and all		
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss			-	-
	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit				
XVI	(Loss) and other comprehensive income for the period)	(0.25	(3.97)	0.22	(3.31
	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59
XVII	I Earnings per Equity Share				
	(1) Basic	(0.01	(0.23)	0.01	(0.19
	(2) Diluted	(0.01		0.01	(0.19

Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 14th August 2023.

2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.

3. Segment Results as per AS is not applicable, as company dealing in only one segment i.e. " Agro Products".

A. No Investor Complaints were received during the quarter ended 30-Jun-2023 nor any pending as on 01-Jul-2023.
Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.



on behalf of the Board Sarda Proteins Ltdo RO U. Deepak Data (DIN: 01672415) Managing Director

Place: Jaipur Date : 14th August, 2023

UDIN :- 23072854 BGVZWV4943



Khetawat Agarwal & Co.

Chartered Accountants

Limited Review Report Unaudited Standalone Quarterly Results

To The Board of Directors Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of SARDA PROTEINS LTD for the Quarter ended on 30th June, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co. **Chartered Accountants** FRN: 003960C

M.L. Agarwal Partner M. No.: 072854

UDIN : 23072854BGVZWV4943 Place : Jaipur Date : 14.08.2023

* ?

ed Accov